Clinical trials: Nash
Nonalcoholic Fatty Liver Disease, Physician
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
This trial studies patient and physician perspectives on non-alcoholic fatty liver disease. Using questionnaires and interviews, this trial may help researchers understand physicians' knowledge about the diagnosis, prognosis…
- Trial name
- NCT04132440
- Testing
- Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
This study is conducted to test the hypothesis that in uncontrolled type 2 diabetic adults treatment with diacerein will improve glycemic control and will reduce liver fat within a 24 month period.
- Trial name
- DGCLFT2DM (NCT02242149)
- Testing
- Diacerein
- Where
- Brazil
- Volunteers
- 84 people
- Sponsor
- Universidade Federal do Rio de Janeiro
NASH - Nonalcoholic Steatohepatitis, Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
This is a single centre, open label, randomized, 3 treatment arms, with and without food dosing, Phase 1b pharmacology study to assess the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Farnesoid X…
- Trial name
- NCT03976687
- Testing
- EYP001a
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Simple Steatosis (SS), Non-alcoholic Steatohepatitis (NASH)
Gut Microbiota and Modulation of Liver Damage in NAFLD
Several experimental data suggest that gut-derived endotoxin and GM composition can act as a "second hit" or insult to convert hepatic SS to NASH and cause both local hepatic and systemic inflammation.This study's aim is to…
- Conditions
- Simple Steatosis (SS), Non-alcoholic Steatohepatitis (NASH), Obesity
- Trial name
- NCT02158351
- Testing
- liver and white adipose tissue biopsies
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- University of Roma La Sapienza
Non-alcoholic Fatty Liver Disease
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
The clinicopathological analyses revealed that reduction in HbA1c and use of insulin independently contribute to the reduction in liver fibrosis scores during the histological course of NAFLD development.
- Trial name
- NCT02649465
- Testing
- Tofogliflozin, Glimepiride
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kanazawa University
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic…
- Trial name
- NCT07902219
- Testing
- Qurse Revand
- Where
- India
- Volunteers
- 128 people
- Sponsor
- National Institute of Unani Medicine, Bengaluru
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
MLCT Oil for Fatty Liver - PASS Trial
The main objective of this randomised pilot study is to explore the relative efficacy of dietary MLCT oil versus LCT oil (corn oil) in augmenting therapy of overweight and obese NAFLD patients with at least a 1-stage reversal…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, NAFLD
- Trial name
- PASS (NCT05217745)
- Testing
- MLCT Oil, LCT Oil (Corn Oil)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
NASH
A Phase II Clinical Trial of Chiglitazar for NASH
The study is to evaluate the efficacy and safety of chiglitazar monotherapy in patients with non-clcoholic steatohepatitis (NASH).
- Trial name
- NCT05193916
- Testing
- chiglitazar sodium tablets
- Where
- 15 sites in China
- Volunteers
- 104 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Non-Alcoholic Fatty Liver Disease
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population and causes serious complications, including cirrhosis, hepatocellular carcinoma or mortality.
- Trial name
- NCT05754385
- Testing
- Ambulatory monitoring of liver fat, Standard of care
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The University of Hong Kong
NASH With Fibrosis, MASH With Fibrosis
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).
- Trial name
- NCT06215716
- Testing
- Efruxifermin
- Where
- 359 sites in United States, Argentina and 16 more
- Volunteers
- 1,650 people
- Sponsor
- Akero Therapeutics, Inc
Non-Alcoholic Fatty Liver Disease, Renal Transplant Complication Pre-Existing Disease
Transient Elastograghy to Detect Non Alcoholic Fatty Liver Disease in Renal Transplantation Recipients.
a. Primary (main): The presence of non alcoholic fatty liver disease in post renal transplantation recipients by non invasive methods as transient elastograghy b-Secondary (subsidiary): to evaluate if transient elastograghy could…
- Trial name
- NCT05894993
- Testing
- transient elastograghy
- Volunteers
- 50 people
- Sponsor
- Amany Khaled Ali Ahmed
NAFLD, NASH - Nonalcoholic Steatohepatitis
The Franciscus Obesity NASH Study
The purpose of this study is to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) changes in terms of steatosis and elasticity in patients with morbid obesity 1, 3 and 5 years after…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid
- Trial name
- FONS (NCT05499949)
- Testing
- NASH screening, Cardiac dysfunction screening, Liver biopsy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Franciscus Gasthuis
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of the metabolic syndrome. NAFLD is a pathologic condition which involves both hepatic steatosis and non alcoholic steatohepatitis (NASH), as…
- Trial name
- NCT01894438
- Testing
- Mediterranean lifestyle, Mediterranean Diet
- Where
- Greece
- Volunteers
- 63 people
- Sponsor
- Harokopio University
Overweight and Obesity, Cardiovascular Diseases
Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)
The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.
- Conditions
- Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2
- Trial name
- SCOOP-RNPC (NCT05857319)
- Testing
- Nutritional Psycho-Behavioral Reeducation Program
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Groupe Éthique et Santé
Non-alcoholic Fatty Liver Disease (NAFLD)
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
- Trial name
- NCT07268937
- Testing
- CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Evaluate the Physiological Stability of NIS4 Biomarker Between the Fed and Fasting State in Patients With the Target Condition (NAFLD)
Evaluation of the Physiological Stability Variability and Robustness of NIS4
Patients at higher risk of progression to cirrhosis and clinical deleterious outcomes are those that have a high grade of necroinflammation together with significant fibrosis.
- Trial name
- NCT06159257
- Testing
- Blood test
- Where
- France
- Volunteers
- 50 people
- Sponsor
- CerbaXpert
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD
The overall goal of this collaborative research program is to develop, validate and translate advanced quantitative magnetic resonance (MR) biomarkers of obesity-associated non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NAFLD (NCT03674528)
- Testing
- Magnetic Resonance Elastography (MRE), Liver biopsy
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Non-Alcoholic Fatty Liver Disease, Obesity
Endoscopic Gastric Plication Using the POSE2.0 Technique for Management of Fatty Liver Disease
Primary Obesity Surgery Endoluminal 2.0, or POSE 2.0, (USGI Medical, San Clemente, CA) creates full-thickness plications of gastric tissue endoscopically to shorten the stomach and narrow its aperture for weight loss in patients…
- Trial name
- NCT05611567
- Testing
- POSE2.0 procedure, Life style and behavioral intervention
- Where
- United Arab Emirates
- Volunteers
- 42 people
- Sponsor
- Emirates Health Services (EHS)
Non-alcoholic Fatty Liver Disease, Obesity
Effect of Exercise on Hepatic Fat in Overweight Children
The objective of the present study is to evaluate the effect of 6 months exercise intervention program on hepatic fat fraction in overweight children.
- Conditions
- Non-alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- EFIGRO (NCT02258126)
- Testing
- Multidisciplinary intervention program
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of the Basque Country (UPV/EHU)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.